Wedbush restated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report issued on Monday, RTT News reports. Wedbush currently has a $15.00 price objective on the stock. Separately, HC Wainwright restated a buy rating and set a $16.00 target price on shares of Inozyme Pharma in a research note […]
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now owns 20,665 […]
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now […]
Wedbush reissued their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Separately, Needham & Company LLC restated a buy rating and issued a $23.00 target price on shares of Inozyme Pharma […]
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price suggests a potential upside of 172.73% from the stock’s current price. Separately, Needham & Company […]